-
February 7, 2024 Lupin Q3 FY2024 Results
-
February 6, 2024 Lupin Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%
-
February 2, 2024 Lupin Launches Cyanocobalamin Nasal Spray in the United States
-
February 1, 2024 Lupin Receives Approval from U.S. FDA for Dronedarone Tablets, USP
-
January 30, 2024 Lupin Digital Health introduces Digital Therapeutics Certificate for Cardiologists in India in collaboration with the American College of Cardiology
-
January 23, 2024 Lupin Receives Tentative Approval from U.S. FDA for Rivaroxaban Tablets USP
-
January 18, 2024 Lupin Receives Approval from U.S. FDA for Febuxostat Tablets
-
January 14, 2024 Lupin Hosts Second Edition of Aptivate Champion Run for Kids
-
January 14, 2024 Lupin Receives Approval from U.S. FDA for Propranolol Hydrochloride Extended-Release Capsules USP
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications